Abstract:Leukemia is a cancer that starts in blood stem cells in the bone marrow. Today, the proper diagnosis and prognosis of leukemia are essential in mitigating the morbidity and mortality associated with this malignancy. The advent of novel biomarkers, particularly those related to minimal residual disease, has paved the way for personalized therapeutic strategies and enables the quantitative assessment of patient responses to treatment regimens. Novel diagnostic and targeted drug delivery may be helpful for the improved management of leukemia. Genetic clinical parameters, such as chromosomal abnormalities, are crucial in diagnosing and guiding treatment decisions. These genetic markers also provide valuable prognostic information, helping to predict patient outcomes and tailor personalized treatment plans. In the present review, the studies on the diagnostic and prognostic parameters of leukemia were analyzed. The prognosis of leukemia was investigated in most of the studies, and the remaining were performed on diagnosis. The clinical and laboratory prognostic parameters were the most common, followed by diagnostic hematological parameters, diagnostic blood parameter studies, and diagnostic immunological parameters. Clinical and laboratory prognostic and hematologic parameters were the most extensively studied. The methods used to diagnose and prognose the leukemia cases in these studies were predominantly clinical hematology. Numerous surface proteins and receptors, including CD45, CD27, CD29, CD38, CD27, CD123, CD56 and CD25, react similarly in various kinds of leukemia, which are ideal for targeted drug delivery. Drug delivery to leukemia cells encounters several significant obstacles, including heterogeneity, that hinder the effectiveness of treatment. Nanocarriers play a critical role in targeted drug delivery for leukemia by enhancing the precision of treatments directed at surface proteins and receptors. Additionally, they can be functionalized with targeting drugs and antibodies to target specific tissues and cells.

Advances of Nanoparticles for Leukemia Treatment

Nano-drug Delivery System for the Treatment of Acute Myelogenous Leukemia.

Targeted therapy for leukemia based on nanomaterials

Nanoparticle-Based Targeted Therapeutics In Head-And-Neck Cancer

Nanoparticles—Emerging Potential for Managing Leukemia and Lymphoma

Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia

Recent Advances in Material Technology for Leukemia Treatments

Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review)

Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia

Nanoparticles: A New Approach to Upgrade Cancer Diagnosis and Treatment

Development and Application of Nanomaterials, Nanotechnology and Nanomedicine for Treating Hematological Malignancies

Nanoparticle-based medicines in clinical cancer therapy

Patient-Specific Nanoparticle Targeting in Human Leukemia Blood

Nanozymes: a new approach for leukemia therapy

Research progress of nanomaterial drug delivery in tumor targeted therapy

Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment

Recent advances of nanodrug delivery system in the treatment of hematologic malignancies

Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia

Delivery strategies in treatments of leukemia

Advances in nano-immunotherapy for hematological malignancies

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia